Compulsive Gambling
Also known as: Gambling addiction
Methodology & AI Transparency ⓘ
Compulsive Gambling Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Many people enjoy gambling, whether it's betting on a horse or playing poker on the Internet.
- 2 Real-world patient consensus: Diagnostic registry Z12.2: Compulsive Gambling is managed within Preventive & Labs (aka Gambling addiction).
- 3 Typical cash cost range: Clinicians assessing Compulsive Gambling focus on early biomarker detection in Compulsive Gambling (Z12.2: allowing low-intensity lifestyle) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Compulsive Gambling: maintaining ApoB, HbA1c & in Compulsive Gambling (Z12.2: hs-CRP Triad) within ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (Z12.2).
Ask our AI Specialists anything about Compulsive Gambling
What Is Compulsive Gambling?
Many people enjoy gambling, whether it's betting on a horse or playing poker on the Internet. Most people who gamble don't have a problem, but some lose control of their gambling. Signs of problem gambling include : Always thinking about gambling Lying about gambling Spending work or family time gambling Feeling bad after you gamble, but not quitting Gambling with money you need for other things If you have concerns about your gambling, ask for help. Your health care provider can work with you to find the treatment that's best for you.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Compulsive Gambling (Z12.2) features early biomarker detection in Compulsive Gambling (Z12.2: allowing low-intensity lifestyle). Cross-referenced with NIH MeSH (Gambling), therapeutic stabilization in preventive & labs is verified against CBC, CMP & in Compulsive Gambling (Z12.2: eGFR Baseline).
Common Symptoms & Clinical Signs
- • Always thinking about gambling
- • Lying about gambling
- • Presentation of Compulsive Gambling (Z12.2): follow-up of borderline in Compulsive Gambling (Z12.2: laboratory values before)
- • Secondary Compulsive Gambling clinical sign: subtle fatigue, recovery in Compulsive Gambling (Z12.2: lag, or micronutrient)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Compulsive Gambling Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Z12.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Compulsive Gambling (Z12.2: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (Z12.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Compulsive Gambling (Z12.2: eGFR Baseline) | Within optimal preventive reference intervals (Z12.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Compulsive Gambling (Z12.2: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (Z12.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Compulsive Gambling
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Clomipramine Hydrochloride Anafranil • RxCUI 857297 | Tricyclic Antidepressant | 74% | $0.1694 | $ 6.77 /mo |
| Esomeprazole Strontium Esomeprazole Strontium Generic • RxCUI RXN-70849400-3187 | Proton Pump Inhibitor | 78% | $6.8110 | $ 185.00 /mo |
| Fluvoxamine Maleate Luvox • RxCUI 903873 | Serotonin Reuptake Inhibitor | 93% | $3.6629 | $ 7.45 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Compulsive Gambling)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Health-related quality of life outcomes with nipocalimab versus placebo in Nipocalimab + SOC demonstrated early and sustained fatigue and HRQoL improvements over 24 weeks. Journal of neurology • 2026-06-26 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42360473 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Conclusion: Treatment with nabiximols does not impair skills relevant to driving in those patients with tic disorders who were fit to drive at baseline and even improved fitness to. Cannabis and cannabinoid research • 2024-10-15 • Phase III Randomized Trial | N = 64 | 88/100 | PMID 38265476 ↗ |
| Can This Approach Help? Inside the Latest Research on N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive We found no evidence supporting the efficacy of the adjunctive use of NAC in OCD. Progress in neuro-psychopharmacology & biological psychiatry • 2022-07-13 • Phase III Randomized Trial | N = 98 | 88/100 | PMID 35304155 ↗ |
| Can This Approach Help? Inside the Latest Research on Secukinumab for Giant Cell Sustained full symptom relief at week 52 did not differ significantly between patients with GCA randomly assigned to receive SEC-300 with a 26-week GC taper versus placebo with a 52-week GC taper. NEJM evidence • 2026-07-15 • Phase III Randomized Trial | N = 140 | 88/100 | PMID 42234457 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of crovalimab versus eculizumab in complement inhibitor-naïve Over 24 weeks, 91% of patients achieved complete terminal complement inhibition with crovalimab. Annals of hematology • 2026-06-13 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42287326 ↗ |
Compulsive Gambling Patient Community & “People Like Me” Threads
Filter Compulsive Gambling community threads and patient logs by age, biological sex, dosage, and treatment duration.